180 related articles for article (PubMed ID: 15917157)
1. Intranasal versus transdermal matrix oestrogen replacement in Australasian women.
Davis SR; Davison SL; Wilson S; Shepherd J; Lawton B
Maturitas; 2005 Jun; 51(2):163-71. PubMed ID: 15917157
[TBL] [Abstract][Full Text] [Related]
2. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
3. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
Palacios S
Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
Adler G; Young D; Galant R; Quinn L; Witchger MS; Maki KC
Gynecol Obstet Invest; 2005; 59(4):212-9. PubMed ID: 15753617
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of intranasal and transdermal estradiol.
Lopes P; Merkus HM; Nauman J; Bruschi F; Foidart JM; Calaf J
Obstet Gynecol; 2000 Dec; 96(6):906-12. PubMed ID: 11084176
[TBL] [Abstract][Full Text] [Related]
6. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
[TBL] [Abstract][Full Text] [Related]
7. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
[TBL] [Abstract][Full Text] [Related]
8. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
9. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
10. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
Baksu B; Baksu A; Göker N; Citak S
Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
[TBL] [Abstract][Full Text] [Related]
11. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
[TBL] [Abstract][Full Text] [Related]
12. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
Mizunuma H
Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
[TBL] [Abstract][Full Text] [Related]
14. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
15. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
16. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
17. Aerodiol versus the transdermal route: perspectives for patient preference.
Lopes P; Rozenberg S; Graaf J; Fernandez-Villoria E; Marianowski L
Maturitas; 2001 Jun; 38 Suppl 1():S31-9. PubMed ID: 11390122
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
Archer DF;
Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
[TBL] [Abstract][Full Text] [Related]
20. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]